For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.16% and ...

Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...

Eli Lilly announces a $15 billion share buyback, three times its previous largest program, highlighting strong financial ...

The Phase III study saw the drug able to cut the risk of disease progression or death by 38% with imlunestrant alone, and ...

Eli Lilly announces positive Phase III EMBER-3 trial results for imlunestrant in advanced breast cancer, showing a 38% ...

Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as ...

Results of the a phase III clinical trial called EMBER-3 indicate the promise and efficacy of a drug called imlunestrant. This is a new kind of oral selective estrogen receptor degrader (SERD), used ...

By Karen Roman Agendia, Inc. said it will present MammaPrint’s ability to predict chemotherapy benefit in patients with early-stage breast cancer at the San Antonio Breast Cancer Symposium 2024. “This ...

Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...

Imlunestrant, given alone or in combination with abemaciclib, has demonstrated efficacy in patients with ER+, HER2- advanced breast cancer.